{
  "id": 20594585,
  "title": "Amphastar at Jefferies Global Healthcare Conference: growth offsets headwinds",
  "url": "https://urgent.news/2026/11/18/amphastar-at-jefferies-global-healthcare-conference-growth-offsets",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-18T12:32:58.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/amphastar-at-jefferies-global-healthcare-conference-growth-offsets-headwinds-93CH-5035806"
  },
  "original_language": "en",
  "account": "On Wednesday, 18 November 2026, Amphastar Pharmaceuticals Inc. (AMPH) showcased impressive third-quarter sales and a thriving pipeline during the Jefferies Global Healthcare Conference, while acknowledging ongoing remediation costs and higher research spending that could impact profits. The company's two flagship products, BAQSIMI and Primatene MIST, both shattered quarterly sales records, despite ongoing challenges tied to 340B discounting issues and repairs at its California facility.\n\nAmphastar reported its highest-ever quarterly sales, driven by record results for BAQSIMI and Primatene MIST, with BAQSIMI sales increasing 10% year-over-year and Primatene MIST sales rising 9% year-over-year. The company also revealed promising sales for newer products, including ipratropium, which generated $8 million in the second quarter and $6.6 million in the third quarter, and teriparatide, which saw a meaningful increase from a year earlier.\n\nManagement highlighted the company's ability to grow despite pressures such as lower pricing on BAQSIMI, glucagon, and epinephrine, as well as remediation spending at the IMS plant. They noted that higher-margin products like BAQSIMI, ipratropium, and teriparatide are improving the overall margin mix. Amphastar is actively pursuing business development and share repurchases, with a preference for larger deals if opportunities arise.\n\nThe CFO, Bill Peters, emphasized that the third quarter was a record period, with sales reaching unprecedented levels. He attributed the company's growth to a combination of record sales for its key products and the emergence of newer products in the market. However, management acknowledged that 2026 remains a transitional year due to remediation efforts and lower pricing on certain products.\n\nThe company is optimistic about the future, with 2027 expected to benefit from easier comparisons as the pricing pressure on BAQSIMI eases. Amphastar is also preparing for the commercial launch of its GLP-1 product in the fourth quarter of 2027, pending FDA approval. The company remains active in exploring new opportunities, such as the launch of its insulin aspart biosimilar, which is now expected to launch commercially in the fourth quarter of 2027, subject to FDA approval.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}